[go: up one dir, main page]

SG10201909412RA - Composition for suppressing muscular fatty change - Google Patents

Composition for suppressing muscular fatty change

Info

Publication number
SG10201909412RA
SG10201909412RA SG10201909412RA SG10201909412RA SG 10201909412R A SG10201909412R A SG 10201909412RA SG 10201909412R A SG10201909412R A SG 10201909412RA SG 10201909412R A SG10201909412R A SG 10201909412RA
Authority
SG
Singapore
Prior art keywords
composition
suppressing
fatty
fatty change
muscular
Prior art date
Application number
Inventor
Yuta Otsuka
Noriyuki Kanzaki
Shuichi Machida
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of SG10201909412RA publication Critical patent/SG10201909412RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

COMPOSITION FOR SUPPRESSING MUSCULAR FATTY CHANGE The object of the invention is to provide a new composition for suppressing fatty degeneration of a muscle, the composition including a component that is safe and suitable for a long term intake. It was found that quercetin or a glycoside thereof suppresses a differentiation process from myosatellite cells into adipocyte-like cells. In the present invention, quercetin or a glycoside thereof is used in a composition for suppressing fatty degeneration of a muscle.
SG10201909412R 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change SG10201909412RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015090580 2015-04-27

Publications (1)

Publication Number Publication Date
SG10201909412RA true SG10201909412RA (en) 2019-11-28

Family

ID=57198430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909412R SG10201909412RA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change
SG11201708158PA SG11201708158PA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201708158PA SG11201708158PA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change

Country Status (8)

Country Link
US (1) US20180104269A1 (en)
JP (1) JP7013238B2 (en)
CN (1) CN107530320A (en)
CA (1) CA2982645C (en)
HK (1) HK1246182A1 (en)
SG (2) SG10201909412RA (en)
TW (1) TW201713330A (en)
WO (1) WO2016175136A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087175A (en) * 2016-11-30 2018-06-07 花王株式会社 Muscle atrophy inhibitor
US20190388387A1 (en) * 2017-03-10 2019-12-26 Suntory Holdings Limited Composition for inhibiting myofibrosis
JP7227962B2 (en) * 2018-04-27 2023-02-22 サントリーホールディングス株式会社 Composition for suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength
CN114745967A (en) * 2019-11-27 2022-07-12 三得利控股株式会社 Composition for inhibiting decrease in muscle mass, inhibiting decrease in muscle strength, increasing muscle mass or increasing muscle strength
CN116648145A (en) * 2020-12-18 2023-08-25 三得利控股株式会社 Composition for improving muscle flexibility
CN114958730A (en) * 2022-04-22 2022-08-30 南京农业大学 Muscle stem cell proliferation medium, differentiation medium and application thereof
JP7679339B2 (en) * 2022-07-19 2025-05-19 サントリーホールディングス株式会社 Composition for enhancing the effect of exercise on reducing body fat
KR102727951B1 (en) * 2023-05-23 2024-11-11 영남대학교 산학협력단 Medium composition for promoting differentiation of muscle cells comprising quercetin as an active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100441590C (en) * 2006-03-10 2008-12-10 中山大学 Metal complexes of quercetin compounds and their glycosides and their applications
JP2008255075A (en) 2007-04-09 2008-10-23 Daidoo Dorinko Kk Vascular endothelial function improving agent and health food
JP2013126951A (en) * 2010-03-01 2013-06-27 Kyushu Univ Muscular atrophy inhibitor
JP2014015428A (en) * 2012-07-10 2014-01-30 Kao Corp Satellite cell differentiation promoter
JP2014037387A (en) * 2012-08-18 2014-02-27 Kobe Gakuin Therapeutic agent for muscular dystrophy
SG10201809153WA (en) * 2014-04-28 2018-11-29 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside

Also Published As

Publication number Publication date
CA2982645C (en) 2024-02-13
HK1246182A1 (en) 2018-09-07
TW201713330A (en) 2017-04-16
WO2016175136A1 (en) 2016-11-03
CA2982645A1 (en) 2016-11-03
JP7013238B2 (en) 2022-01-31
SG11201708158PA (en) 2017-11-29
JPWO2016175136A1 (en) 2018-02-15
CN107530320A (en) 2018-01-02
US20180104269A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
SG10201909412RA (en) Composition for suppressing muscular fatty change
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
MX2019001125A (en) Macrocycle kinase inhibitors.
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EP3250578A4 (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof
SG11201605423UA (en) Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms
EP3250054A4 (en) Oligosaccharide compositions for use as food ingredients and methods of producing thereof
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MY179243A (en) Supplemented fish feed
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2016012835A (en) Compositions and methods for treating blackheads.
MX2017015936A (en) New pharmaceutical composition comprising non-ionic surfactants.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
ZA201706915B (en) Methods and compositions for the treatment of cellulosic biomass and products produced thereby
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2017014971A (en) Enhanced salt compositions and methods of preparation thereof.
PH12022550657A1 (en) Steel compositions, methods of manufacture and uses in producing rimfire cartridges
MX2015001648A (en) Compositions comprising spicamycin derivatives and methods of use thereof.
MX2017007318A (en) Methods of preventing, reducing or treating macular degeneration.
GB2528406A (en) Prebiotic composition and method of its use
HUP1400082A2 (en) Deodorant composition produced by natural ingredients and process for its preparation
MX2018009810A (en) Microcapsules and process for preparation of microcapsules.